Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Not Applicable
Completed
- Conditions
- Non-small Cell Lung Cancer Patients
- Interventions
- Procedure: 18F-FDG-PET scan
- Registration Number
- NCT02043002
- Lead Sponsor
- University of Aarhus
- Brief Summary
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking.
Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
- Lung Cancer patients with non-small cell histology and stage IV disease
- candidate for erlotinib treatment as first/ second/ third line of treatment
Read More
Exclusion Criteria
- pregnancy
- severe dyspnoea
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-FDG-PET scan 18F-FDG-PET scan An early evaluation 18F-FDG-PET scan after 7-10 days
- Primary Outcome Measures
Name Time Method 18F-FDG-PET evaluation Time to progression and latest april 2015 (up to 2 years) Standardized Uptake Values (SUV) will be used as measurement of 18F-FDG uptake
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus, Jylland, Denmark